2023
Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes
Frampton J, Kearney K, Abbott J, Kereiakes D, Di Mario C, Saito S, Cristea E, Riley R, Fajadet J, Shlofmitz R, Ali Z, Klein A, Price M, Hill J, Stone G, Lansky A. Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101069. PMID: 39129889, PMCID: PMC11307843, DOI: 10.1016/j.jscai.2023.101069.Peer-Reviewed Original ResearchIntravascular lithotripsyLesion failureIschemia-driven target lesion revascularizationMajor adverse cardiac event ratesAdverse cardiac event ratesDrug-eluting stent placementMajor adverse cardiac eventsSmaller reference vessel diameterTarget vessel myocardial infarctionCoronary intravascular lithotripsyAdverse cardiac eventsCardiac event ratePrimary end pointTarget lesion failureTarget lesion revascularizationVessel myocardial infarctionReference vessel diameterAdverse clinical eventsHigh procedural successSex-based outcomesSex-specific outcomesLesion revascularizationAngiographic outcomesCardiac eventsCardiac death
2020
Long‐term serial functional evaluation after implantation of the Fantom sirolimus‐eluting bioresorbable coronary scaffold
Saito Y, Cristea E, Bouras G, Abizaid A, Lutz M, Carrié D, Weber‐Albers J, Dudek D, Anderson J, Lansky A, Investigators T. Long‐term serial functional evaluation after implantation of the Fantom sirolimus‐eluting bioresorbable coronary scaffold. Catheterization And Cardiovascular Interventions 2020, 97: 431-436. PMID: 32077590, DOI: 10.1002/ccd.28804.Peer-Reviewed Original ResearchConceptsPost-percutaneous coronary interventionQuantitative flow ratioBioresorbable coronary scaffoldTarget vessel revascularizationVessel revascularizationFunctional ischemiaStable coronary artery diseaseTime of revascularizationCoronary artery diseaseFractional flow reserveQFR assessmentII trialAngiographic outcomesCoronary interventionUnstable anginaArtery diseaseQFR valueWire-based fractional flow reserveSignificant lesionsFlow reservePatientsTarget vesselRevascularizationQFR analysisFunctional evaluationDefining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology.
Chang CC, Kogame N, Onuma Y, Byrne RA, Capodanno D, Windecker S, Morel MA, Cutlip DE, Krucoff MW, Stone GW, Lansky AJ, Mehran R, Spitzer E, Fraser AG, Baumbach A, Serruys PW. Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. EuroIntervention 2020, 15: 1190-1198. PMID: 31475907, DOI: 10.4244/eij-d-19-00552.Peer-Reviewed Original ResearchConceptsDevice success rateDrug-eluting stentsPercutaneous coronary intervention trialsCoronary intervention trialsDevice successIntervention trialsClinical trialsSuccess rateSymptomatic coronary artery diseasePercutaneous coronary interventionAdverse clinical eventsCoronary artery diseasePercutaneous Cardiovascular InterventionsDifferent trialsRevascularisation proceduresCoronary interventionAngiographic outcomesArtery diseaseClinical eventsComparative trialsEndpoint definitionsDrug AdministrationCardiovascular interventionsPerformance endpointEuropean Association
2011
Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Hermiller JB, Nikolsky E, Lansky AJ, Applegate RJ, Sanz M, Yaqub M, Sood P, Cao S, Sudhir K, Stone GW. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention 2011, 7: 307-13. PMID: 21729832, DOI: 10.4244/eijv7i3a54.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsPercutaneous coronary interventionSegment restenosisYounger patientsElderly patientsLower incidenceSegment late lumen lossSegment late lossSPIRIT III trialTarget vessel failureLate lumen lossDrug-eluting stentsYears of ageThree-year resultsLower ratesAge-specific mechanismsStent assignmentAngiographic outcomesCoronary interventionIII trialsInducible ischaemiaEE patientsPE patientsLumen lossNeointimal response
2009
Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry
Gordon PC, Applegate RJ, Hermiller JB, Weinsier SB, Doostzadeh J, Cao S, Sudhir K, Lansky AJ, Stone GW. Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry. Catheterization And Cardiovascular Interventions 2009, 75: 179-186. PMID: 19877267, DOI: 10.1002/ccd.22259.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProspective StudiesRegistriesRisk AssessmentSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsMajor adverse cardiac eventsTarget vessel failureSegment late lossSPIRIT III trialLarge coronary arteriesPaclitaxel-eluting stentsLate lossCoronary arteryIII trialsXIENCE VDe novo native coronary artery lesionsNovo native coronary artery lesionsNative coronary artery lesionsPE armSPIRIT IIIAdverse cardiac eventsCoronary artery lesionsAdverse clinical eventsAngiographic late lossEES patientsNoninferior ratesPrimary endpointAngiographic outcomesArtery lesionsCardiac events
2008
Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial.
Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, Mehran R, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MW. Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. Journal Of Invasive Cardiology 2008, 20: 335-41. PMID: 18599890.Peer-Reviewed Original ResearchMeSH KeywordsAngiographyAngioplasty, Balloon, CoronaryBlood GlucoseCoronary Artery DiseaseDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Drug-Eluting StentsFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMiddle AgedProspective StudiesRetrospective StudiesSingle-Blind MethodStentsTreatment OutcomeConceptsMajor adverse cardiovascular eventsPercutaneous coronary interventionDiabetic patientsAngiographic outcomesAdverse outcomesTaxus stentStent deploymentBare metal stent deploymentAdverse cardiovascular eventsMultivessel coronary diseaseTarget vessel revascularizationImproved clinical outcomesAngiographic restenosisCardiovascular eventsVessel revascularizationCoronary interventionCoronary diseaseGlycemic controlMultivessel stentingClinical outcomesDiabetic cohortElevated HbA1cLate lumenPatientsDiabetesComparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial
Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ, Investigators F. Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial. JAMA 2008, 299: 1903-1913. PMID: 18430909, DOI: 10.1001/jama.299.16.1903.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDrug-Eluting StentsEverolimusFemaleHumansImmunosuppressive AgentsLogistic ModelsMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesSingle-Blind MethodSirolimusUltrasonography, InterventionalConceptsMajor adverse cardiac eventsAdverse cardiac eventsPaclitaxel-eluting stentsSegment late lossSecondary end pointsTarget vessel failureCoronary artery diseaseCardiac eventsLate lossEnd pointArtery diseaseComposite major adverse cardiac eventsAdditional secondary end pointsMajor secondary end pointLesion revascularization proceduresSPIRIT III trialPrimary end pointReference vessel diameterPercutaneous coronary interventionEverolimus-Eluting StentsAngiographic late lossCobalt-chromium stentAgents everolimusNoninferior ratesAngiographic outcomes
2007
Impact of Baseline Platelet Count in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the CADILLAC Trial)
Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M, Mehran R, Lansky AJ, Na Y, Stone GW. Impact of Baseline Platelet Count in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the CADILLAC Trial). The American Journal Of Cardiology 2007, 99: 1055-1061. PMID: 17437727, DOI: 10.1016/j.amjcard.2006.11.066.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCause of DeathCoronary AngiographyCoronary RestenosisCoronary ThrombosisCreatine KinaseFemaleFollow-Up StudiesForecastingHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet CountPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecurrenceStentsTreatment OutcomeConceptsPrimary percutaneous coronary interventionBaseline platelet countAcute myocardial infarctionPrimary PCIHigher baseline platelet countPercutaneous coronary interventionPlatelet countCoronary interventionMyocardial infarctionAngiographic success rateTarget vessel thrombosisPowerful independent predictorMedian platelet countRole of plateletsCADILLAC trialCardiac mortalityAngiographic outcomesIndependent predictorsAngiographic resultsHighest quartileMultivariable analysisVessel thrombosisVascular responsesReinfarctionPatients
2006
Serial Angiographic Follow-Up of Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Revascularization
Price MJ, Cristea E, Sawhney N, Kao JA, Moses JW, Leon MB, Costa RA, Lansky AJ, Teirstein PS. Serial Angiographic Follow-Up of Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Revascularization. Journal Of The American College Of Cardiology 2006, 47: 871-877. PMID: 16487858, DOI: 10.1016/j.jacc.2005.12.015.Peer-Reviewed Original ResearchConceptsLate lossParent vesselUnprotected left main coronary artery stenosisLeft main coronary artery stenosisFinal minimal luminal diameterMain coronary artery revascularizationMain coronary artery stenosisSirolimus-eluting stent implantationEfficacy of SESCoronary artery revascularizationAngiographic Follow-upSirolimus-Eluting StentsCoronary artery stenosisMinimal luminal diameterArtery revascularizationCircumflex ostiumLesion restenosisLesion revascularizationLMCA diseaseLMCA interventionLMCA lesionsSES implantationAngiographic outcomesIndependent predictorsArtery stenosis
2005
Angiographic and clinical outcomes at 8 months of cutting balloon angioplasty and β‐brachytherapy for native vessel in‐stent restenosis (BETACUT): Results from a stopped randomized controlled trial
Schlüter M, Tübler T, Lansky AJ, Kähler S, Berger J, Mathey DG, Schofer J. Angiographic and clinical outcomes at 8 months of cutting balloon angioplasty and β‐brachytherapy for native vessel in‐stent restenosis (BETACUT): Results from a stopped randomized controlled trial. Catheterization And Cardiovascular Interventions 2005, 66: 320-326. PMID: 16216024, DOI: 10.1002/ccd.20517.Peer-Reviewed Original ResearchConceptsStandard balloonClinical outcomesCB angioplastyBalloon angioplastyStent restenosisInterim analysisMajor adverse cardiac eventsNative vesselsAdverse cardiac eventsOverall patient populationImmediate angiographic outcomeTreatment of choiceQuantitative coronary angiographyΒ-brachytherapyAngiographic restenosisBeta-radiation treatmentLesion revascularizationAngiographic outcomesCardiac eventsConsecutive patientsCoronary angiographyStudy armsIntracoronary brachytherapyPatient populationTreatment modalitiesSirolimus-Eluting versus Bare Nitinol Stent for Obstructive Superficial Femoral Artery Disease: The SIROCCO II Trial
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Mudde C, Tielemans H, Bérégi JP. Sirolimus-Eluting versus Bare Nitinol Stent for Obstructive Superficial Femoral Artery Disease: The SIROCCO II Trial. Journal Of Vascular And Interventional Radiology 2005, 16: 331-338. PMID: 15758128, DOI: 10.1097/01.rvi.0000151260.74519.ca.Peer-Reviewed Original ResearchConceptsSirolimus-eluting stent groupStent groupBare stent groupMean lumen diameterSignificant differencesLumen diameterSuperficial femoral artery diseaseSuperficial femoral artery obstructionChronic limb ischemiaFemoral artery diseaseFemoral artery obstructionAnkle-brachial indexBinary restenosis rateDouble-blind studySymptoms of claudicationBare nitinol stentsSirolimus-eluting stentsStandard interventional techniquesArtery obstructionPrimary endpointII trialAdverse eventsAngiographic outcomesArtery diseaseLimb ischemia
2004
Gamma radiation for in‐stent restenosis: effect of lesion length on angiographic and clinical outcomes
Mehran R, Iakovou I, Dangas G, Lansky AJ, Stone GW, Mintz GS, Kent KM, Pichard AD, Satler LF, Fahy M, Leon MB, Waksman R. Gamma radiation for in‐stent restenosis: effect of lesion length on angiographic and clinical outcomes. Catheterization And Cardiovascular Interventions 2004, 61: 354-359. PMID: 14988895, DOI: 10.1002/ccd.10786.Peer-Reviewed Original ResearchConceptsISR groupLesion lengthClinical eventsIn-Stent Restenosis TrialBaseline lesion lengthLower late lossShort lesion groupTreatment of ISRStent restenosis lesionsLong-term outcomesRecurrent ISRRestenosis lesionsRestenosis TrialAngiographic outcomesISR lesionsRestenosis rateClinical outcomesWashington RadiationLate lossStent restenosisLumen dimensionsLong ISRRadiation treatmentPowerful predictorPatients
2003
Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis
Shirai K, Lansky AJ, Mintz GS, Costantini CO, Fahy M, Mehran R, Dangas G, Moses JW, Stone GW, Waksman R, Leon MB. Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. The American Journal Of Cardiology 2003, 92: 1409-1413. PMID: 14675575, DOI: 10.1016/j.amjcard.2003.08.047.Peer-Reviewed Original ResearchConceptsMinimum lumen diameterVascular brachytherapyLesion lengthSegment restenosisAngiographic outcomesStent restenosisFinal minimum lumen diameterRandomized clinical trialsIndependent angiographic predictorsAngiographic restenosisPlacebo groupAngiographic predictorsAngiographic resultsMultivariable analysisNative coronariesVessel sizeClinical trialsLesion complexityVBT groupRestenosisLumen diameterSimilar reductionPlaceboGreater reductionLesionsBenefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW. Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction. Circulation 2003, 108: 1316-1323. PMID: 12939213, DOI: 10.1161/01.cir.0000087601.45803.86.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyEndpoint DeterminationFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexStentsTreatment OutcomeConceptsComposite end pointTarget vessel revascularizationIschemia-driven target vessel revascularizationPrimary percutaneous coronary interventionAbciximab treatmentPercutaneous coronary interventionAcute myocardial infarctionMyocardial infarctionCoronary interventionEnd pointPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsInfarct artery reocclusionPrespecified secondary analysisEvent-free survivalFactorial design trialLack of effectAbciximab useAngiographic substudyCADILLAC trialTVR ratesPrimary angioplastyPrimary stentingAngiographic outcomesRelation between the degree of procedural anticoagulation and complications after coronary stent implantation
Ashby DT, Dangas G, Aymong EA, Farkouh ME, Mehran R, Lansky AJ, Moses JW, Leon MB, Stone GW. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. The American Journal Of Cardiology 2003, 92: 319-322. PMID: 12888144, DOI: 10.1016/s0002-9149(03)00637-4.Peer-Reviewed Original Research
2002
Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial
Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L, investigators I. Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. The Lancet 2002, 359: 551-557. PMID: 11867107, DOI: 10.1016/s0140-6736(02)07741-3.Peer-Reviewed Original ResearchConceptsBinary angiographic restenosis ratePrimary safety endpointAngiographic restenosis rateTarget lesion revascularisationStent restenosisPlacebo groupSafety endpointRestenosis rateRadiated groupMyocardial infarctionMajor adverse cardiac eventsIntracoronary beta radiationIntracoronary β-radiationSuccessful coronary interventionAdverse cardiac eventsPrimary efficacy endpointRecurrence of restenosisBeta-radiation treatmentEfficacy endpointAngiographic outcomesCardiac eventsCoronary interventionIntracoronary stentingProcedural successVascular brachytherapy
2001
Acute and 6‐month clinical and angiographic outcome after implantation of the ACS Duet stent for single‐vessel coronary artery disease: Final results of the European and U.S. ACS Multi‐link Duet Registry
Foley D, Kererakes D, Riele J, Nishimura N, Veldhof S, Fink S, Yeung A, van Hoogenhuyze D, Lansky A, van Es G, Kutryk M, Serruys P. Acute and 6‐month clinical and angiographic outcome after implantation of the ACS Duet stent for single‐vessel coronary artery disease: Final results of the European and U.S. ACS Multi‐link Duet Registry. Catheterization And Cardiovascular Interventions 2001, 54: 25-33. PMID: 11553944, DOI: 10.1002/ccd.1233.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseArtery diseaseSingle-vessel coronary artery diseaseMajor adverse cardiac eventsNative coronary artery lesionsObstructive coronary artery diseaseEffective percutaneous treatmentAdverse cardiac eventsCoronary artery lesionsProspective observational studyMinimum luminal diameterQuantitative coronary angiographyCoronary stent systemAdequate predilatationAngiographic outcomesArtery lesionsCardiac eventsCoronary angiographyPercutaneous treatmentRestenosis rateTarget lesionsLate outcomesLuminal diameterObservational studyStent systemComparison of self-expanding and balloon-expandable stents for the reduction of restenosis
Han R, Schwartz R, Kobayashi Y, Wilson S, Mann J, Sketch M, Safian R, Lansky A, Popma J, Fitzgerald P, Palacios I, Chazin-Caldie M, Goldberg S, in the Appendix. F. Comparison of self-expanding and balloon-expandable stents for the reduction of restenosis. The American Journal Of Cardiology 2001, 88: 253-259. PMID: 11472703, DOI: 10.1016/s0002-9149(01)01636-8.Peer-Reviewed Original ResearchConceptsNative coronary arteriesIntravascular ultrasound examinationBalloon-expandable stentsSE stentsCoronary arteryBE stentsMajor adverse cardiac eventsAdverse cardiac eventsBinary restenosis rateCoronary angiographic characteristicsSubgroup of patientsMinimum stent areaReduction of restenosisAngiographic characteristicsAngiographic outcomesBaseline demographicsBypass surgeryCardiac eventsRestenosis rateRestenotic lesionsIntimal proliferationIVUS analysisMyocardial infarctionUltrasound examinationLate lossFinal results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries
Baim D, Cutlip D, Midei M, Linnemeier T, Schreiber T, Cox D, Kereiakes D, Popma J, Robertson L, Prince R, Lansky A, Ho K, Kuntz R, Investigators A. Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. The American Journal Of Cardiology 2001, 87: 157-162. PMID: 11152831, DOI: 10.1016/s0002-9149(00)01308-4.Peer-Reviewed Original ResearchConceptsTarget vessel failurePS stentPalmaz-SchatzMajor adverse cardiac eventsNative vessel lesionsAdverse cardiac eventsPrimary end pointNative coronary arteriesSuccessful stent deliveryPalmaz-Schatz stentsAngiographic outcomesCardiac eventsAngiographic restudyAcute resultsDiameter stenosisVessel lesionsCoronary arteryVessel failureClinical equivalenceStent deliveryNonsignificant trendPatientsExcellent deliverabilityEnd pointStents
2000
Importance of lesion length on new device angioplasty of native coronary arteries
Saucedo J, Kennard E, Popma J, Talley D, Lansky A, Leon M, Baim D. Importance of lesion length on new device angioplasty of native coronary arteries. Catheterization And Cardiovascular Interventions 2000, 50: 19-25. PMID: 10816274, DOI: 10.1002/(sici)1522-726x(200005)50:1<19::aid-ccd4>3.0.co;2-h.Peer-Reviewed Original ResearchConceptsTarget lesion revascularizationNew device angioplastyMore target lesion revascularizationLesion revascularizationLong lesionsLesion lengthRight coronary artery diseaseSmaller minimal lumen diameterLong lesion groupMore multivessel diseaseNative coronary arteriesCoronary artery diseaseCoronary Intervention RegistryEarly clinical eventsMinimal lumen diameterLonger lesion lengthMultivessel diseaseAngiographic outcomesIntervention RegistryArtery diseaseClinical outcomesHospital eventsTotal occlusionClinical eventsCoronary artery